drugset / Trial / NCT00170768

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

NCT00170768

Phase 2 Completed 150 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.

Timeline

Start
2005-02
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 15 mg
Comparator Oxybutynin Small molecule 20 mg

Indications

No indication recorded.